CureVac AG
14 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
4
Ending by 2030
Jan 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Dec 4 to 27, 2026 · next Dec 4
- 3 fees due Jan 4 to 11, 2027 · next Jan 4
- 3 fees due Feb 6 to 28, 2027 · next Feb 6
- 1 fee due Mar 19, 2027The maintenance fee for Artificial Nucleic Acid Molecules for Improved Protein Expression (US 11,761,009) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
- 4 fees due Apr 8 to 17, 2027 · next Apr 8
- 1 fee due Jun 30, 2027The maintenance fee for Dry Powder Composition Comprising Long-Chain RNA (US 10,517,827) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 3 fees due Jul 5 to 12, 2027 · next Jul 5
- 3 fees due Sep 5 to 24, 2027 · next Sep 5
- 4 fees due Oct 7 to 23, 2027 · next Oct 7
- 1 fee due Nov 7, 2027The maintenance fee for Vaccination with mRNA-coded antigens (US 11,975,064) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,421,038 | RNA-coded antibody In force · From the USPTO record | In force | From the USPTO record | |
| US 10,434,154 | Composition for treating prostate cancer (PCa) In force · From the USPTO record | In force | From the USPTO record | |
| US 10,441,653 | Nucleic acid comprising GlXmGn as an immune-stimulating agent/adjuvant In force · From the USPTO record | In force | From the USPTO record | |
| US 10,111,967 | Complexes of RNA and cationic peptides for transfection and for immunostimulation In force · From the USPTO record | In force | From the USPTO record | |
| US 8,968,746 | Complexation of Nucleic Acids with Disulfide-Crosslinked Cationic Components for Transfection and Immunostimulation In force · High confidence | In force | High confidence | |
| US 9,234,013 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Protein In force · High confidence | In force | High confidence | |
| US 9,839,697 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Protein In force · Low confidence | In force | Low confidence | |
| US 10,010,592 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Tumour Antigen In force · High confidence | In force | High confidence | |
| US 10,232,024 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Allergenic Antigen or an Autoimmune Self-Antigen In force · High confidence | In force | High confidence | |
| US 10,653,799 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Protein In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 134: 14 patents in force now held by others · 24 lapsed for an unpaid fee · 6 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
45 pending · 18 abandoned · 127 no status recorded